223488-57-1

Basic information

• Product Name: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid
• Synonyms: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid;CP-533536;Evatanepag
• CAS NO: 223488-57-1
• Molecular Formula: C₂₅H₂₈N₂O₅S
• Molecular Weight: 468.56
• Mol File: 223488-57-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 660.15 °C at 760 mmHg
• Flash Point: 353.046 °C
• Appearance: /
• Density: 1.262 g/cm³
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(223488-57-1)
• EPA Substance Registry System: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(223488-57-1)

Safety Data

• Hazardous Substances Data: 223488-57-1(Hazardous Substances Data)

Usage

Uses

Evatanepag is an EP2 receptor selective prostaglandin E2 agonist that helps induce bone growth.

Upstream product

• 223492-52-2 {3-[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy acetic acid tert-butyl ester 

Downstream Products

• 1126076-53-6 (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt monohydrate 
• 223490-49-1 CP-533,536 

Relevant articles and documents

POLYMORPHS OF PROSTAGLANDIN AGONISTS AND METHODS FOR MAKING THE SAME

The present invention relates to polymorphic crystalline forms or a non- crystalline form or amorphous of the compound (3-(((4-tert-butyl-benzyl)-(pyridine- 3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof together with pro

Methods of treatment using an EP2 selective receptor agonist

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Controlled release polymeric compositions of bone growth promoting compounds

The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.